Editas Medicine vs Spero Therapeutics
Spero Therapeutics is the larger business, with $66.8m of revenue in fiscal 2025 against $40.5m for Editas Medicine (1.6 times as much). Spero Therapeutics grew faster (39.2% against 25.4%). Spero Therapeutics kept more of each dollar of sales as profit: a net margin of 12.8% against -395.0%. Spero Therapeutics carries less debt relative to equity (0.2% against 214.8%).
| Latest fiscal year | Editas MedicineEDIT, 2025 | Spero TherapeuticsSPRO, 2025 |
|---|---|---|
| Revenue | $40.5m | $66.8m |
| Revenue growth | 25.4% | 39.2% |
| Net income | −$160m | $8.6m |
| Operating margin | -394.9% | 9.5% |
| Net margin | -395.0% | 12.8% |
| Return on equity | -198.1% | 16.3% |
| Free cash flow | −$166m | −$12.6m |
| Cash | $147m | $40.3m |
| Total debt | $58.6m | $91,000 |
| Debt to equity | 214.8% | 0.2% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 87 | 25 |
| Market value | $252m | $60.5m |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | 11 (Weak) |
| Insider trades, 12 months | 0 buys, 14 sales | 0 buys, 9 sales |